Peringkat dalam Saham
#29650
Medivir AB (publ) is a pharmaceutical company established in 1987 and... Medivir AB (publ) is a pharmaceutical company established in 1987 and headquartered in Huddinge, Sweden. It is dedicated to the research, development, and global commercialization of medicines, with a primary focus on oncology. The company currently markets Zoviduo (formerly Xerclear) for the treatment of labial herpes. Its robust development pipeline includes Remetinostat, targeting MF cutaneous T-cell lymphoma and basal cell carcinoma; MIV-818, aimed at liver cancer; and MIV-711, being advanced for osteoarthritis. Additionally, Medivir is progressing Birinapant and IGM-8444 for various solid tumor indications. Collaborative efforts are also key to its strategy, including a research partnership with SciLifeLab's Drug Discovery and Development Platform to discover antivirals for SARS CoV-2, alongside licensing agreements with Tango Therapeutics for a preclinical research program and with Ubiquigent Limited for the USP7 preclinical research program.
Harga Saham
$0.68377137
Terakhir disinkronkan: 2023-05-23
Kapitalisasi Pasar
$20.23M
Perubahan (1 hari)
-0.60%
Perubahan (1 tahun)
0.00%
Perdagangan Medivir AB (publ) (MVIR-B)
Harga MVIR-B dengan kapitalisasi pasar B
Kapitalisasi pasar dari Medivir AB (publ)(MVIR-B)
Kapitalisasi Pasar: $20.23M
Per August 2026, Medivir AB (publ) memiliki kapitalisasi pasar sebesar $20.23M. Ini menjadikan Medivir AB (publ) sebagai perusahaan 29650th paling bernilai di dunia menurut data kami. Kapitalisasi pasar adalah nilai total saham beredar dari perusahaan publik dan biasanya digunakan untuk mengukur seberapa besar nilai sebuah perusahaan.
Riwayat kapitalisasi pasar Medivir AB (publ) dari 2000 hingga 2026
MVIR-B dibandingkan dengan 5 teratas stocks paling populer
| Harga MVIR-B |
|
Aset B |
Pasar B |
Hasil |
|
|
|
|
$5.307T
|
+26,236,559.14%
|
|
|
|
|
$4.551T
|
+22,499,511.59%
|
|
|
|
|
$4.154T
|
+20,539,797.21%
|
|
|
|
|
$3.589T
|
+17,742,300.50%
|
|
|
|
|
$2.797T
|
+13,827,998.65%
|
